XBIO - Xenetic Biosciences VolitionRx collaborate to develop cell therapies to treat cancer

• Biopharmaceutical firm Xenetic Biosciences ( NASDAQ: XBIO ) and VolitionRx ( NYSE: VNRX ), a developer of blood tests, have signed a research and development agreement for certain targeted cell therapies to treat cancer, the companies said on Tuesday.
• Xenetic ( XBIO ) stock had lost 5.4% to $0.87 in premarket trading, while shares of VolitionRx ( VNRX ) had gained 6.5% to $2.13. VNRX separately announced another R&D collaboration agreement with Salarius Pharmaceuticals ( SLRX ).
• XBIO and VNRX will develop neutrophil extracellular traps (NETs) which are net-like structures composed of DNA complexes and proteins. They are involved in cancer progression and metastatic dissemination.
• The R&D collaboration will evaluate the potential combination of VNRX's Nu.Q NETs Test and XBIO's CAR-T platform to develop cell therapies for the potential treatment of cancer.
• VolitionRx ( VNRX ) will fund the research program and the two parties will share proceeds from any products licensed or commercialized under the collaboration.

For further details see: